TCGA data (https://www.proteinatlas.org/) confirmed the results that HCC patients with high NAP1L1 expression predicted poorer overall survival in both TNM stage I–II and III–IV, respectively (p < 0.001 and p < 0.001, Fig. 2c, d). This evidence concerns the gene NAP1L1 and hepatocellular carcinoma.